Clinigen Group PLC operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Clinigen Group PLC with three other
miscellaneous service companies in Europe:
sales of 1.82 billion Danish Kroner [US$284.66 million]
of which 100%
Bachem Holding AG
(236.48 million Swiss Francs [US$247.88 million]
of which 89%
was Active Pharmaceutical Ingredients), and
(£388.30 million [US$504.29 million]
of which 45%
was Operating Genus PIC).
During the year ended June of 2016, sales at
Clinigen Group PLC were £339.90 million (US$441.43 million).
increase of 84.4%
versus 2015, when the company's sales were £184.36 million.
This was the fifth consecutive year of sales increases at Clinigen Group PLC
(and since 2011, sales have increased a total of 870%).
Sales of Global Access saw an increase
that was more than double the company's growth rate: sales were up
330.1% in 2016, from
£9.21 million to £39.60 million.
Clinigen Group PLC also saw significant increases in sales in
Managed Access (up 250.1% to £100.80 million)